A phase Ib bioequivalence study of ALZ-801 to determine the pharmacokinetics and food effect in healthy elderly volunteers for the treatment of Alzheimer's Disease

Trial Profile

A phase Ib bioequivalence study of ALZ-801 to determine the pharmacokinetics and food effect in healthy elderly volunteers for the treatment of Alzheimer's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs ALZ 801 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Most Recent Events

    • 17 Jul 2017 According to an Alzheon meddia release, data from this trial will be presented at the Alzheimers Association International Conference 2017.
    • 30 Mar 2017 Results from this and another phase Ib trial (CT profile 700266591) Presented at the 13th International Conference on Alzheimer's and Parkinson's Diseases, according to an Alzheon Inc. media release.
    • 25 Jul 2016 Status changed from recruiting to completed, according to an Alzheon media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top